Effect of Prostaglandin Analogues on Central Corneal Thickness:3-Year Follow-up Results

Purpose@#To evaluate the effects of each subgroup of prostaglandin analogues (PGAs) on central corneal thickness (CCT) in patients with normal tension glaucoma (NTG). @*Methods@#We retrospectively reviewed 55 eyes of 55 patients with NTG who were receiving PGA therapy. Patients who were treated with 0.005% latanoprost (16 eyes), 0.0015% tafluprost (16 eyes), or 0.004% travoprost (23 eyes) monotherapy were included. CCT assessments were performed at baseline and 1, 2, and 3 years after initiation of treatment. @*Results@#In the NTG group, the mean CCT showed a decreasing trend, and there was a significant difference in mean CCT at 1, 2, and 3 years compared with baseline (baseline, 538.16 ± 32.14; 1 year, 526.55 ± 37.30 µm [p = 0.00]; 2 years, 521.67 ± 36.79 µm [p = 0.00]; 3 years, 520.43 ± 36.88 µm [p = 0.00]). The reduction of CCT was confirmed by subgroup analysis. In the 0.005% latanoprost group, mean CCT was decreased at 1 year (p = 0.11), 2 years (p = 0.00), and 3 years (p = 0.02). In the 0.0015% ta-fluprost group and the 0.004% travoprost group, mean CCT was also significantly decreased at all years (p = 0.00). No statisti-cal difference was observed between the NTG subgroups (p = 0.06). @*Conclusions@#Topical therapy with PGAs appeared to cause a significant decrease in CCT reduction in patients with NTG. A long-term follow-up study including more participants is needed.

Comparison of the Outcomes of Two- and Three-muscle Surgery in Exotropia over 45 Prism Diopters

PURPOSE: We report the outcomes of two- or three-muscle surgery on patients with large-angle exotropia exceeding 45 prism diopters (PDs). METHODS: We retrospectively analyzed data on 45 exotropia patients (> 45 PDs) who underwent two- or three-muscle surgery. We excluded patients with paralytic or restrictive strabismus, A- or V-pattern strabismus, a coexistent oblique dysfunction or nystagmus, and/or a history of prior extraocular muscle surgery. Only patients for whom at least 6 months of follow-up data were available were included. Successful surgery was defined as postoperative esotropia ≤ 5 PD, orthophoria, and exotropia ≤ 10 PD at the last visit. RESULTS: We included 45 patients, of whom 22 and 23 underwent two- and three-muscle surgery, respectively. The mean postoperative deviations were 9.5 and 2.7 PD in the two- and three-muscle groups, respectively; the overall success rates were 54.55% (12/22) and 91.30% (21/23). Subgroup analyses revealed that the surgical success rate of two-muscle operations was 66.67% (12/18) in 45–55 PD patients and 0% (0/4) in ≥ 55 PD patients; the success rates of three-muscle operations were 100% (7/7) and 87.50% (14/16). The success rate did not differ significantly between those with postoperative deviations of 45–55 PD (p = 0.137), but did between those who underwent two- and three-muscle operations to treat postoperative deviations of ≥ 55 PD (p = 0.003). CONCLUSIONS: Satisfactory results can be achieved via two-muscle surgery in patients with exotropia 55 PD, three-muscle surgery is superior to two-muscle surgery. Therefore, large-angle exotropia is optimally treated via three-muscle surgery.

Prognostic Factors for Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Dexamethasone Implant

PURPOSE: To investigate the prognostic factors of visual and anatomic outcomes in patients with diabetic macular edema (DME) treated with intravitreal injection of dexamethasone implant. METHODS: We retrospectively studied 32 eyes of 31 patients with DME for best-corrected visual acuity (BCVA), central macular thickness, and height and width of both intraretinal fluid (IRF) and subretinal fluid. Logistic regression analysis was used to examine correlations between the baseline characteristics and outcomes at 3 and 6 months. RESULTS: Baseline predictor of BCVA ≥20 / 40 at month 3 was short height of baseline IRF (p = 0.02), while good baseline BCVA was a predictor for month 6 (p = 0.01). Predictors of improvement in logarithm of minimum angle of resolution BCVA 0.2 at month 3 were the absence of baseline IRF and poor baseline BCVA (p = 0.02 and p = 0.009, respectively), while poor baseline BCVA was the sole predictor at month 6 (p = 0.01). Predictor of central macular thickness ≤300 µm at month 3 was younger age (p = 0.03), while the absence of IRF was the predictor for BCVA improvement at month 6 (p = 0.02). BCVA ≤20 / 100 at month 3 was predicted by poor baseline BCVA (p = 0.01), and increased width of total IRF was the predictor at month 6 (p = 0.02). Predictor of loss of logarithm of minimum angle of resolution BCVA 0.2 at month 6 was increased width of total IRF at baseline (p = 0.04). Additional injection within 6 months was negatively associated with the presence of baseline DME (p = 0.03). CONCLUSIONS: The visual and anatomical outcome of DME treatment with dexamethasone implant can be predicted by baseline visual acuity and IRF morphology.